Updated molecular testing guideline strongly recommends ROS1 testing for NSCLC


An 2018 update to the lung cancer molecular testing guideline says testing for ROS1 rearrangements is strongly recommended for all lung cancer patients regardless of clinical characteristics. The article “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors” was published online January 23, 2018, in the Journal of … Continue reading Updated molecular testing guideline strongly recommends ROS1 testing for NSCLC

#ROS1 Presentations at ESMO 2017


The European Society for Medical Oncology will hold their annual Congress in Madrid, Spain, on September 8-12 this year.  The three presentations that will discuss ROS1 specifically are listed below (you can see the complete abstracts by clicking on the presentation title). 1308PD – Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small … Continue reading #ROS1 Presentations at ESMO 2017

Ignyta publishes Q2 2017 update on entrectinib for ROS1


Ignyta recently published an update on results from the STARTRK-2 trial of entrectinib. The report had promising results for ROS1+ non-small cell lung cancer (NSCLC) patients who have not taken other targeted therapies, especially those patients who have brain metastases. Patients who responded saw a response within the first three months on the drug. When the … Continue reading Ignyta publishes Q2 2017 update on entrectinib for ROS1

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)


Crizotinib, also known as Xalkori, is a targeted therapy medication prescribed to many patients with ROS1+ cancer. It can be a very effective treatment and relatively tolerable, as cancer treatments go. However, as with most medications, patients may experience side effects. According to the Xalkori.com website, “The most common side effects of Xalkori include: vision … Continue reading Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)